S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, Forecast & News

$3.29
-0.17 (-4.91 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$3.28
Now: $3.29
$3.46
50-Day Range
$3.08
MA: $3.65
$4.18
52-Week Range
$2.39
Now: $3.29
$6.04
Volume428,107 shs
Average Volume524,201 shs
Market Capitalization$180.87 million
P/E RatioN/A
Dividend YieldN/A
Beta1.33
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PIRS
CUSIPN/A
Phone857-246-8998

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.10 million
Book Value$0.74 per share

Profitability

Net Income$-26,750,000.00
Net Margins-107.24%

Miscellaneous

Employees107
Market Cap$180.87 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive PIRS News and Ratings via Email

Sign-up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.


Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) posted its earnings results on Monday, November, 11th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.18. The biotechnology company had revenue of $15.13 million for the quarter, compared to the consensus estimate of $6.28 million. Pieris Pharmaceuticals had a negative return on equity of 132.02% and a negative net margin of 107.24%. View Pieris Pharmaceuticals' Earnings History.

When is Pieris Pharmaceuticals' next earnings date?

Pieris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Pieris Pharmaceuticals.

What price target have analysts set for PIRS?

4 Wall Street analysts have issued 1 year target prices for Pieris Pharmaceuticals' stock. Their forecasts range from $5.00 to $7.00. On average, they expect Pieris Pharmaceuticals' stock price to reach $6.00 in the next year. This suggests a possible upside of 82.4% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals.

What is the consensus analysts' recommendation for Pieris Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals.

What are Wall Street analysts saying about Pieris Pharmaceuticals stock?

Here are some recent quotes from research analysts about Pieris Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany. " (11/28/2019)
  • 2. William Blair analysts commented, "Wenzel is considered a global expert in the treatment of asthma and has extensive experience in conducting clinical trials in asthma patients, having been a lead author on the Phase II trials of Dupixent (Wenzel et al., 2016) and a co-author in the Phase III pivotal trial. The call reaffirmed that FeNO is a well-validated clinical marker of biological activity in patients with asthma, and our belief that there is a significant market opportunity for PRS-060, an inhaled Anticalin targeting IL-4Rα." (8/16/2019)
  • 3. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and price target of $7. Currently our valuation is based on the three lead assets at the company: (1) PRS-060 for asthma, which is partnered with AstraZeneca contributing 33% of our valuation; (2) PRS-343 for oncology, which currently contributes 39% of our valuation; and (3) PRS-080 for functional iron deficiency anemia contributing 28% of our valuation. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (8/1/2019)

Has Pieris Pharmaceuticals been receiving favorable news coverage?

News headlines about PIRS stock have been trending positive on Friday, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pieris Pharmaceuticals earned a daily sentiment score of 2.2 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Pieris Pharmaceuticals.

Are investors shorting Pieris Pharmaceuticals?

Pieris Pharmaceuticals saw a decline in short interest during the month of November. As of November 29th, there was short interest totalling 1,780,000 shares, a decline of 14.0% from the November 14th total of 2,070,000 shares. Based on an average daily trading volume, of 758,700 shares, the short-interest ratio is presently 2.3 days. Approximately 3.7% of the shares of the stock are sold short. View Pieris Pharmaceuticals' Current Options Chain.

Who are some of Pieris Pharmaceuticals' key competitors?

What other stocks do shareholders of Pieris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Verastem (VSTM), TG Therapeutics (TGTX), Exelixis (EXEL), Nektar Therapeutics (NKTR), Omeros (OMER), Aratana Therapeutics (PETX) and Progenics Pharmaceuticals (PGNX).

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen S. Yoder, CEO, Pres & Director (Age 43)
  • Dr. Allan Reine, Sr. VP, CFO & Treasurer (Age 44)
  • Dr. Louis A. Matis, Sr. VP & Chief Devel. Officer (Age 68)
  • Mr. Claus Schalper MBA, Co-Founder & Sr. Advisor
  • Maria Kelman, Director of Investor Relations

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (1.77%), Clear Harbor Asset Management LLC (0.36%), Strs Ohio (0.21%), Creative Planning (0.19%), Massachusetts Financial Services Co. MA (0.19%) and Virtu Financial LLC (0.12%). Company insiders that own Pieris Pharmaceuticals stock include Bvf Partners L P/Il, Christopher P Kiritsy, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.

Which major investors are selling Pieris Pharmaceuticals stock?

PIRS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp, First Quadrant L P CA, Strs Ohio and Barclays PLC. View Insider Buying and Selling for Pieris Pharmaceuticals.

Which major investors are buying Pieris Pharmaceuticals stock?

PIRS stock was bought by a variety of institutional investors in the last quarter, including Clear Harbor Asset Management LLC, Virtu Financial LLC, Alpine Group USVI LLC, Alpine Group USVI LLC, NJ State Employees Deferred Compensation Plan, Meeder Asset Management Inc., Metropolitan Life Insurance Co NY and Massachusetts Financial Services Co. MA. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Christopher P Kiritsy and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $3.29.

How big of a company is Pieris Pharmaceuticals?

Pieris Pharmaceuticals has a market capitalization of $180.87 million and generates $29.10 million in revenue each year. The biotechnology company earns $-26,750,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Pieris Pharmaceuticals employs 107 workers across the globe.View Additional Information About Pieris Pharmaceuticals.

What is Pieris Pharmaceuticals' official website?

The official website for Pieris Pharmaceuticals is http://www.pieris.com/.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]


MarketBeat Community Rating for Pieris Pharmaceuticals (NASDAQ PIRS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  247 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe PIRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PIRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel